Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Assets (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Current Assets for 6 consecutive years, with $78.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 1774.34% to $78.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $78.5 million, a 1774.34% increase, with the full-year FY2024 number at $98.5 million, up 592.78% from a year prior.
  • Current Assets was $78.5 million for Q3 2025 at Inhibikase Therapeutics, down from $88.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $98.5 million in Q4 2024 to a low of $4.2 million in Q3 2024.
  • A 5-year average of $37.8 million and a median of $26.0 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: crashed 76.13% in 2024, then soared 1774.34% in 2025.
  • Inhibikase Therapeutics' Current Assets stood at $42.5 million in 2021, then plummeted by 42.62% to $24.4 million in 2022, then tumbled by 41.69% to $14.2 million in 2023, then soared by 592.78% to $98.5 million in 2024, then fell by 20.23% to $78.5 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Current Assets are $78.5 million (Q3 2025), $88.8 million (Q2 2025), and $94.2 million (Q1 2025).